Arya Mani

Olujimi Ajijola

eLife assessment
In this small-scale study, Fawaz et al. report a significant prevalence of somatic mutations such as Clonal Hematopoiesis of Indeterminate Potential (CHIP) and mosaic loss of Y chromosome (mLOY), but lack of their association with a history of myocardial infarction (MI). The study utilized sensitive techniques, including targeted high-throughput sequencing and digital PCR. The valuable findings by the authors present a contrast to earlier reports, yet they align somewhat with some studies that have demonstrated little or no link between clonal hematopoiesis and atherothrombotic events. Although the study offers convincing results, its limited sample size and brief follow-up period preclude drawing definitive conclusions.

anonymous

Reviewer #1 (Public Review):
This manuscript examines the individual and dual effects of CHIP and LOY in MI employing a cohort of ~460 individuals. CHIP is assessed by NGS and LOY is assessed by PCR. The threshold for CHIP is set at 2% (an arbitrary cutoff that is often used) and LOY at 9% (according to the Discussion text - this reviewer may have missed the section that describes why this threshold was employed). The investigation assessed whether LOY could modulate inflammation, atherosclerotic burden, or MI risk associated with CHIP. Neither CHIP nor LOY independently affected hsCRP, atherosclerotic burden, or MI incidence, nor did LOY presence diminish these outcomes in CHIP+ male subjects.
This study represents the first dual analysis of CHIP and LOY on CVD outcomes. The results are largely negative, contradictory to other studies (many with much larger sample sizes). I would attribute the limitation of sample size as a major contributor to the negative data. While the negative data are suspect, the "positive" finding that LOY abolishes the prognostic significance of CHIP on MI is of interest (and consistent with what is understood from mechanistic studies).
Overall, I enjoyed reading the paper, and it is of interest to the research community. However, I disagree with some of the authors' interpretations of the data. Generally, many conclusions on CHIP interpretation are based on the comparison of findings from very large datasets that have been evaluated by shallow NGS DNA sequencing. These studies lack sensitivity and accuracy, but this is counterbalanced by their very large sample sizes. Thus, they draw conclusions from the sickest individuals (ICD codes) with the largest clones (explaining the 10% VAF threshold). Here, the study has a well-phenotyped cohort, but as far as this reviewer can tell, the DNA sequencing is "shallow" NGS. Typically, to assess smaller datasets, investigators employ an error-correction method (DNA barcodes, duplex sequencing, etc.) for the sensitivity and accuracy of calling variants. Thus, the current study appears to suffer from this limitation (small sample sizes combined with NGS).
While the "negative" data from this study are inconclusive, the positive data (i.e. CHIP being prognostic for MI in the absence but not presence of MI) is of interest. Thus, the investigators may want to consider a shorter report that largely focuses on this finding.

Reviewer #2 (Public Review):
Summary:
The preprint by Fawaz et al. presents the findings of a study that aimed to assess the relationship between somatic mutations associated with clonal hematopoiesis (CHIP) and the prevalence of myocardial infarction (MI). The authors conducted targeted DNA sequencing analyses on samples from 149 MI patients and 297 non-MI controls from a separate cohort. Additionally, they investigated the impact of the loss of the Y chromosome (LOY), another somatic mutation frequently observed in clonally expanded blood cells. The results of the study primarily demonstrate no significant associations, as neither CHIP nor LOY were found to be correlated with an increased prevalence of MI. Of note, the null findings regarding CHIP are in conflict with several larger studies in the literature.
Strengths:
Overall, this is a useful research work on an emerging risk factor for cardiovascular disease (CVD). The use of a targeted sequencing approach is a strength, as it offers higher sensitivity than the whole exome sequencing approaches used in many previous studies.
Weaknesses:
Reporting null findings is definitely relevant in an emerging field such as the role of somatic mutations in cardiovascular disease. Nevertheless, the study suffers from severe limitations, which casts doubts on the authors' conclusions, as detailed below:
(1) The small sample size of the study population is a critical limitation, particularly when reporting null findings that conflict (partly) with positive findings in much larger studies, totaling hundreds of thousands of individuals (e.g. Zekavat et al, Nature CVR 2023, Vlasschaert et al, Circulation 2023; Zhao et al, JAMA Cardio 2024). The authors claim that they have 90% power to detect an effect size of CHIP on MI comparable to that in a previous report (Jaiswal et al, NEJM 2017). However, the methodology used to estimate statistical power is not described. Furthermore, the work by Jaiswal et al (NEJM 2017) showed a hazard ratio of approx. 2.0, but more recent work in much larger populations suggests that the overall effect of CHIP on atherosclerotic CVD is smaller, most likely due to the heterogeneity of effects of different mutated genes (e.g. Zekavat et al, Nature CVR 2023, Vlasschaert et al, Circulation 2023; Zhao et al, JAMA Cardio 2024). In addition, several analyses in the current manuscript are conducted separately in MI(+) (n= 149) and MI(-) (N=297) individuals, further limiting statistical power. Power is still lower in the investigation of the effects of LOY and its interaction with CHIP, as only men are included in these analyses. Overall, I believe the study is severely underpowered, which calls into question the validity of the reported null findings.
(2) Related to the above, it is widely accepted that the effects of CHIP on CVD are highly heterogeneous, as some mutated genes appear to have a strong impact on atherosclerosis, whereas the effect of others is negligible (e.g. Zekavat et al, Nature CVR 2023, Vlasschaert et al, Circulation 2023, among others). TET2 mutations are frequently considered a "positive control", given the multiple lines of evidence suggesting that these mutations confer a higher risk of atherosclerotic disease. However, no association with MI or related variables was found for TET2 mutations in the current work. Reporting the statistical power specifically for assessing the effect of TET2 mutations would enhance the interpretation of these results.
(3) One of the most essential features of CHIP is the tight correlation with age. In this study, the effect of age on CHIP (Supplementary Tables S5, S6) seems substantially milder than in previous studies. Given the relatively weak association with age here, it is not surprising that no association with MI or atherosclerotic disease was found, considering that this association would have a much smaller effect size. In addition, there are previous reports of sex-related differences in the prevalence of CHIP, is there an association between CHIP and age after adjusting for sex?
(4) The mutated genes included in the definition of "CHIP" here are markedly different than those in most previous studies, particularly when considering specifically the studies that demonstrated an association between CHIP and atherosclerotic CVD. For instance, the definition of CHIP in this manuscript includes genes such as ANKRD26, CALR, CCND2, and DDX41... that are not prototypical CHIP genes. This is unlikely to have a major impact on the main results, as the vast majority of mutations detected are indeed in bona fide CHIP genes, but it should be at least acknowledged. Furthermore, the strategy used here for the CHIP variant calling and curation seems substantially different than that used in previous studies, which precludes a direct comparison. This is important because such differences in the definition of CHIP and the curation of variants are the basis of most conflicting findings in the literature regarding the effects of this condition. Ideally, the authors should conduct sensitivity analyses restricted to prototypical CHIP genes, using the criteria that have been previously established in the field (e.g. Vlasschaert et al, Blood 2023).
(5) An important limitation of the current study is the cross-sectional design of most of the analyses. For instance, it is not surprising that no association is found between CHIP and prevalent atherosclerosis burden by ultrasound imaging, considering that many individuals may have developed atherosclerosis years or decades before the expansion of the mutant clones, limiting the possible effect of CHIP on atherosclerosis burden. Similarly, the analysis of the relationship between CHIP and a history of MI may be confounded by the potential effects of MI on the expansion of mutant clones. In this context, it is noteworthy that the only positive results here are found in the analysis of the relationship between CHIP at baseline and incident MI development over follow-up. Increasing the sample size for these longitudinal analyses would provide deeper insights into the relationship between CHIP and MI.
(6) The description of some analyses lacks detail, but it seems that statistical analyses were exclusively adjusted for age or age and sex. The lack of adjustment for conventional cardiovascular risk factors in statistical analyses may confound results, particularly given the marked differences in several variables observed between groups.
(7) The variant allele fraction (VAF) threshold for identifying clinically relevant clonal hematopoiesis is still a subject of debate. The authors state that subjects without any detectable mutation or with mutations with a VAF below 2% were considered non-CHIP carriers. While this approach is frequent in the field, it likely misses many impactful mutations with lower VAFs. Such false negatives could contribute to the null findings reported here. Ideally, the authors should determine the lower detection limit of their sequencing approach (either computationally or through serial dilution experiments) and identify the threshold of VAF that can be detected reliably with their sequencing assay. The association between CHIP and MI should then be evaluated considering all mutations above this VAF threshold, in addition to sensitivity analyses with other thresholds frequent in the literature, such as 1% VAF, 2% VAF, and 10% VAF.
(8) The authors should justify the use of 3D vascular ultrasound imaging exclusively in the supra-aortic trunk. I am not familiar with this technique, but it seems to be most typically used to evaluate atherosclerosis burden in superficial vascular beds such as carotids or femorals. I am concerned about the potential impact of tissue depth on the accurate quantification of atherosclerosis burden in the current study (e.g. <a href="https://doi.org/10.1016/j.atherosclerosis.2016.03.002">https://doi.org/10.1016/j.atherosclerosis.2016.03.002</a>). It is unclear whether the carotids or femorals were imaged in the study population.
(9) The specific criteria used to define LOY need to be justified. LOY is stated to be defined based on a "A cut off of 9% of cells with mLOY defined the detection of a mLOY based on the study of 30 men of less than 40 years who had a normal karyotype as assessed by conventional cytogenetic study." As acknowledged by the authors, this definition of LOY is substantially different than that used in recent studies employing the same technique to detect LOY (Mas-Peiro et al, EHJ 2023). In addition, it seems essential to provide more detailed information on the ddPCR assay used to determine LOY, including the operating range and, more importantly, the lower limit of detection (%LOY) of the assay. A dilution series of a control DNA with no LOY would be helpful in this context.
(10) Our understanding of the relationship between CHIP and CVD is evolving fast, and the manuscript should be considered in the context of recent literature in the field. For instance, the recent work by Zhao et al (JAMA Cardio 2024, doi:10.1001/jamacardio.2023.5095) should be considered, as it used a similar targeted DNA sequencing approach as the one used here, but found a clear association between CHIP and coronary heart disease (in a population of 6181 individuals).
(11) The use of subjective terms like "comprehensive" or "thorough" in the title of the manuscript does not align with the objective nature of scientific reporting.

Comprehensive Evaluation of Clonal Hematopoiesis and Mosaic Loss of Y Chromosome in Cardiovascular Risk: A Thorough Analysis in prospective studies

Figures and data

CHIP, mLOY and their combination are as frequent in MI(+) and MI(-) subjects

Characteristics of the population at the time of inclusion

CHIP and mLOY are not associated with increased hsCRP level

CHIP and mLOY are not associated with an increased atherosclerotic burden

CHIP and mLOY do not increase significantly the risk of incident MI, but could accelerate it in male subjects.

Be the first to read new articles from eLife